Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

Gilead’s Kite Phar­ma is sep­a­rat­ing from its cell ther­a­py joint ven­ture with Fo­s­un Phar­ma in Chi­na, hand­ing Fo­s­un the reins for its CAR-T ther­a­py Yescar­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER